Lifeboat Foundation

Michael Levin is a Distinguished Professor in the Biology department at Tufts University. He holds the Vannevar Bush endowed Chair and serves as director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. To explore the algorithms by which the biological world implemented complex adaptive behavior, he got dual B.S. degrees, in CS and in Biology and then received a PhD from Harvard University. He did post-doctoral training at Harvard Medical School, where he began to uncover a new bioelectric language by which cells coordinate their activity during embryogenesis. The Levin Lab works at the intersection of developmental biology, artificial life, bioengineering, synthetic morphology, and cognitive science.

✅EPISODE LINKS:
👉Round 1: https://youtu.be/v6gp-ORTBlU
👉Mike’s Website: https://drmichaellevin.org/
👉New Website: https://thoughtforms.life.
👉Mike’s Twitter: https://twitter.com/drmichaellevin.
👉Mike’s YouTube: https://youtube.com/@drmichaellevin.
👉Mike’s Publications: https://tinyurl.com/yc388vvk.
👉The Well: https://www.youtube.com/watch?v=0a3xg4M9Oa8 & https://youtu.be/XHMyKOpiYjk.
👉Aeon Essays: https://aeon.co/users/michael-levin.

Continue reading “What is The Field of Diverse Intelligence? Hacking the Spectrum of Mind & Matter | Michael Levin” »

Welcome to another exciting episode of our podcast series, where we dive deep into the world of science and innovation! In today’s episode, we have the privilege of interviewing Prof. Michael Levin, a renowned researcher in the fields of bioelectricity, regenerative biology, and biophysics.

Prof. Levin is the director of the Allen Discovery Center at Tufts University and has been making groundbreaking discoveries that are revolutionizing the field of regenerative medicine. His research focuses on understanding the electrical communication within and between cells, and how this communication can be harnessed for tissue repair and regeneration.

Continue reading “-Electricity of Life💡: Wonders of Bioelectricity and Regenerative Biology Prof Michael Levin” »

Throughout Gray’s life before she got the treatment, the deformed, sickle-shaped red blood cells caused by the genetic disorder would regularly incapacitate her with intense, unpredictable attacks of pain. Those crises would send Gray rushing to the hospital for pain medication and blood transfusions. She could barely get out of bed many days; when she became a mom, she struggled to care for her four children and couldn’t finish school or keep a job.

But then she received the treatment on July 2, 2019. Doctors removed some of her bone marrow cells, genetically modified them with CRISPR and infused billions of the modified cells back into her body. The genetic modification was designed to make the cells produce fetal hemoglobin, in the hopes the cells would compensate for the defective hemoglobin that causes the disease.

A Mississippi woman’s life has been transformed by a treatment for sickle cell disease with the gene-editing technique CRISPR. All her symptoms from a disease once thought incurable have disappeared.

Continue reading “Sickle cell patient’s success with gene editing raises hopes and questions” »

What happens when humans begin combining biology with technology, harnessing the power to recode life itself.

What does the future of biotechnology look like? How will humans program biology to create organ farm technology and bio-robots. And what happens when companies begin investing in advanced bio-printing, artificial wombs, and cybernetic prosthetic limbs.

Continue reading “GENETIC ENGINEERING & BIOTECHNOLOGY in the Future (2077 & Beyond)” »

The findings suggest that adenosine base editing raised the expression of fetal hemoglobin to higher, more stable, and more uniform levels than other genome editing technologies that use CRISPR/Cas9 nuclease in human hematopoietic stem cells.

“Ultimately, we showed that not all genetic approaches are equal,” said Jonathan Yen, PhD, genome engineering group director at St. Jude Children’s Research Hospital. “Base editors may be able to create more potent and precise edits than other technologies. But we must do more safety testing and optimization.”

SCD and beta-thalassemia are blood disorders caused by mutations in the gene encoding hemoglobin affecting millions of people. Restoring gene expression of an alternative hemoglobin subunit active in a developing fetus has previously shown therapeutic benefit in SCD and beta-thalassemia patients. The researchers wanted to find and optimize genomic technology to edit the fetal hemoglobin gene.

Continue reading “Base Editing Beats Other Genome Editing Strategies for Treating Sickle Cell Disease” »

“A major highlight of the work is our approach to achieve longevity: using computers to simulate the natural aging system and guide the design and rational engineering of the system to extend lifespan,” Hao told Motherboard. “This is the first time this computationally-guided engineering-based approach has been used in aging research. Our model simulations actually predicted that an oscillator can double the lifespan of the cell, but we were happily surprised that it actually did in experiments.”

The study is part of a growing corpus of mind-boggling research that may ultimately stave off some of the unpleasant byproducts of aging until later in life, while boosting life expectancy in humans overall. Though countless hurdles have to be cleared before these treatments become a reality, Hao thinks his team’s approach could eventually be applied to humans.

“I don’t see why it cannot be applied to more complex organisms,” Hao said. “If it is to be introduced to humans, then it will be a certain form of gene therapy. Of course it is still a long way ahead and the major concerns are on ethics and safety.”

Nominations are now open for the 3D Printing Industry Awards 2023. Who are the leaders in 3D printing? Find out on November 30th when the winners across twenty categories will be announced during a London-based live awards ceremony.

A team of scientists from the University of Sydney and the Children’s Medical Research Institute (CMRI) at Westmead have leveraged 3D photolithographic printing to fabricate functional human tissues that accurately mimic an organ’s architecture.

The researchers utilized bioengineering and cell culture techniques to instruct stem cells derived from blood cells and skin cells to become specialized. These specialized cells can then form organ-like structures.

Welcome to this special issue, focusing on the potential of pluripotent stem cell (PSC)-based therapies and their paths toward clinical application. Since the establishment of human embryonic stem (ES) and induced pluripotent stem (iPS) cells in 1998 and 2007, respectively, significant progress has been made in differentiating PSCs into a broad range of somatic cells. We are now closer than ever before to having highly functional PSC-derived somatic cells at purity for transplantation therapies to complement damaged or diseased organs and restore their physiologic functions. Like organ transplantation, PSC-based therapies have the potential to regenerate damaged organs that cannot otherwise be healed by using small-molecule or antibody-based drugs.

In this issue, Kobold et al. present an overview of the history and current status of clinical studies utilizing human PSCs. Since the early 2010s, many clinical studies employing human ES cells have been initiated. By 2018, the number of such studies using human iPS cells had skyrocketed. Many PSC-based therapies are currently being tested to treat various pathologic conditions, including different neoplasms and diseases of the eye, adnexa, and circulatory system. However, there are still many diseases that require further efforts to interrogate the true potential of PSC-based therapies. To advance the use of PSC-based therapy to treat a wider range of pathologic conditions in the future, we must continue with extensive basic and clinical research to establish both efficacy and safety for such new therapies.

Although clinical research on PSC-based therapy for liver diseases has not received as much attention, there is much hope for it to become a real alternative to living-donor liver transplantation. Cardinale et al. provided a comprehensive summary of the recent studies on cell-based therapy for liver diseases. In addition, artificial livers generated through bioengineering efforts are now considered to be a viable option. Aside from traditional cell or organ transplantation to restore impaired liver function, transplantation aimed at treating the microenvironment, such as inflammation, in the liver is also an effective therapeutic strategy. Concurrent research efforts in both basic and clinical studies will be crucial in making PSC-based therapy for liver diseases a reality.

Physicist Luke MacQueen combines tissue engineering with stem cell technologies to produce synthetic meat whose texture mimics that of natural meat.

Winston Churchill—the well-known wartime leader and lesser-known Nobel Laureate in Literature—published an essay in 1931 in The Strand Magazine in which he imagined the future “Fifty Years Hence.” Many of his predictions turned out to be prophetic—wireless telephones, television, and nuclear power—while others read like science fiction. But one of his futuristic ideas—growing meat in a lab—may just be a few years away, if Luke MacQueen of Harvard University has his way.